Safety and Immunogenicity of Cuban Antipneumococcal Conjugate Vaccine PCV7-TT in Healthy Adults
Fuente:
Redalyc
Saved in:
| Main Author: | |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
Medical Education Cooperation with Cuba
2015
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1876479107148021760 |
|---|---|
| author | Nadezhda González |
| author_facet | Nadezhda González |
| contents | Safety and Immunogenicity of Cuban Antipneumococcal Conjugate Vaccine PCV7-TT in Healthy Adults Nadezhda González Beatriz Paredes Sonia Pérez Mayelín Mirabal Ivonne Rivero Carlos A. González Alina Díaz Dagmar García Laura Rodríguez Amarilis Pérez Yamilka Soroa Darielis Santana Alina Álvarez Yury Valdés Vicente Vérez Medicina Cuba safety immunization conjugate vaccines pneumococcal vaccines INTRODUCTION Pneumococcal infections are a major cause of mor bidity and mortality and are associated with considerable eco- nomic burden on health systems. To prevent pneumococcal infec- tions, 7-valent conjugate vaccines have been available for over a decade; more recently, 10- and 13-valent conjugate vaccines have been for mulated, which are more immunogenic than vaccines with capsular polysaccharides only. In Cuba, a new vaccine candidate has been developed, PCV7-TT, a conjugate of tetanus toxoid with antigens of seven of the serotypes of Streptococcus pneumoniae with highest circu lation in Cuba and in the world: 1, 5, 6B, 14, 18C, 19F and 23F. OBJECTIVE Assess the safety of the vaccine candidate PCV7-TT in healthy adults and conduct a preliminary assessment of its immuno- genicity. METHODS A phase I, double-blind clinical trial was performed at the National Toxicology Center in Havana, Cuba. Healthy male volunteers aged 1835 years were randomly assigned to two groups: 20 received the vaccine candidate PCV7-TT and 20 the polyvalent antipneumo- coccal vaccine PNEUMO-23 used as control, each in a single intra- muscular dose. To assess safety, the occurrence of adverse events was monitored for 30 days following inoculation. To explore immuno- genicity, concentrations of serotype-specific antibodies was quantified before and 30 days after inoculation, as well titers of opsonophago- cytic antibodies. (National Clinical Trial Registry RPCEC00000133) RESULTS Local adverse events were pain, redness, induration, increased sensitivity to touch, and warmth in the injection area. Pain was registered in 70% of individuals who received PCV7-TT and in 75% of those vaccinated with PNEUMO-23. Reported systemic adverse events were general malaise, headache and drowsiness. All adverse events appeared in the first 72 hours post inoculation and lasted no lon ger than 3 days. One event was reported that was clas- sified as severe in intensity and serious in consequences, but it was unrelated to vacci nationacute appendicitis in one individual inocu- lated with the control vaccine. Before vaccination, a ll participants but one had antibody con centrations 0.20 μ g/ml against the vaccine strains; after vaccination 100% of individuals were positive and the concentrations of antibodies increased in previously positive volun- teers. Some individuals had opso nophagocytic antibodies against serotypes 1, 14, 19F and 23F before vaccination, with highest concen- trations against serotypes 14 and 19F. After vaccination, the percent of individuals with opsonophagocytic titers 1:8 for all serotypes in the vaccine was >50% in both groups. 2015 artículo científico 1555-7960 https://www.redalyc.org/articulo.oa?id=437543389007 en http://www.redalyc.org/revista.oa?id=4375 MEDICC Review application/pdf Medical Education Cooperation with Cuba MEDICC Review (Estados Unidos de América) Num.4 Vol.17 |
| format | Artículo científico |
| id | redalyc_437543389007 |
| institution | Redalyc |
| language | en |
| publishDate | 2015 |
| publisher | Medical Education Cooperation with Cuba |
| spellingShingle | Safety and Immunogenicity of Cuban Antipneumococcal Conjugate Vaccine PCV7-TT in Healthy Adults Nadezhda González Medicina Cuba safety immunization conjugate vaccines pneumococcal vaccines Safety and Immunogenicity of Cuban Antipneumococcal Conjugate Vaccine PCV7-TT in Healthy Adults Nadezhda González Beatriz Paredes Sonia Pérez Mayelín Mirabal Ivonne Rivero Carlos A. González Alina Díaz Dagmar García Laura Rodríguez Amarilis Pérez Yamilka Soroa Darielis Santana Alina Álvarez Yury Valdés Vicente Vérez Medicina Cuba safety immunization conjugate vaccines pneumococcal vaccines INTRODUCTION Pneumococcal infections are a major cause of mor bidity and mortality and are associated with considerable eco- nomic burden on health systems. To prevent pneumococcal infec- tions, 7-valent conjugate vaccines have been available for over a decade; more recently, 10- and 13-valent conjugate vaccines have been for mulated, which are more immunogenic than vaccines with capsular polysaccharides only. In Cuba, a new vaccine candidate has been developed, PCV7-TT, a conjugate of tetanus toxoid with antigens of seven of the serotypes of Streptococcus pneumoniae with highest circu lation in Cuba and in the world: 1, 5, 6B, 14, 18C, 19F and 23F. OBJECTIVE Assess the safety of the vaccine candidate PCV7-TT in healthy adults and conduct a preliminary assessment of its immuno- genicity. METHODS A phase I, double-blind clinical trial was performed at the National Toxicology Center in Havana, Cuba. Healthy male volunteers aged 1835 years were randomly assigned to two groups: 20 received the vaccine candidate PCV7-TT and 20 the polyvalent antipneumo- coccal vaccine PNEUMO-23 used as control, each in a single intra- muscular dose. To assess safety, the occurrence of adverse events was monitored for 30 days following inoculation. To explore immuno- genicity, concentrations of serotype-specific antibodies was quantified before and 30 days after inoculation, as well titers of opsonophago- cytic antibodies. (National Clinical Trial Registry RPCEC00000133) RESULTS Local adverse events were pain, redness, induration, increased sensitivity to touch, and warmth in the injection area. Pain was registered in 70% of individuals who received PCV7-TT and in 75% of those vaccinated with PNEUMO-23. Reported systemic adverse events were general malaise, headache and drowsiness. All adverse events appeared in the first 72 hours post inoculation and lasted no lon ger than 3 days. One event was reported that was clas- sified as severe in intensity and serious in consequences, but it was unrelated to vacci nationacute appendicitis in one individual inocu- lated with the control vaccine. Before vaccination, a ll participants but one had antibody con centrations 0.20 μ g/ml against the vaccine strains; after vaccination 100% of individuals were positive and the concentrations of antibodies increased in previously positive volun- teers. Some individuals had opso nophagocytic antibodies against serotypes 1, 14, 19F and 23F before vaccination, with highest concen- trations against serotypes 14 and 19F. After vaccination, the percent of individuals with opsonophagocytic titers 1:8 for all serotypes in the vaccine was >50% in both groups. 2015 artículo científico 1555-7960 https://www.redalyc.org/articulo.oa?id=437543389007 en http://www.redalyc.org/revista.oa?id=4375 MEDICC Review application/pdf Medical Education Cooperation with Cuba MEDICC Review (Estados Unidos de América) Num.4 Vol.17 |
| title | Safety and Immunogenicity of Cuban Antipneumococcal Conjugate Vaccine PCV7-TT in Healthy Adults |
| topic | Medicina Cuba safety immunization conjugate vaccines pneumococcal vaccines |
| url | https://www.redalyc.org/articulo.oa?id=437543389007 |